| ²é¿´: 1764 | »Ø¸´: 5 | |||
[½»Á÷]
¡¾ÇóÖú¡¿ÇóÖú¹ØÓÚÒÁÅËÁ¢ÍªµÄ˵Ã÷Êé
|
| ¹úÍâ¹ØÓÚÒÁÅËÁ¢Íª±¾ÉíµÄÏà¹ØÎÄÏ×±¨µÀ£¬ËµÃ÷Ê鼰רÀû¾ù¿É¡£ÏÈлл´ó¼Ò£¡ |
» ²ÂÄãϲ»¶
ºÓ±±Ò½¿Æ´óѧҩѧÏà¹Ø×¨Òµ½ÓÊܵ÷¼Á
ÒѾÓÐ20È˻ظ´
¡¾ÕÐÆ¸¡¿Ç廪´óѧҩѧԺǮ·æ½ÌÊÚ¿ÎÌâ×é³ÏƸ²©Ê¿ºó
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ120È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
аæscifinder
ÒѾÓÐ1È˻ظ´
°²½ÝÂ×ÒºÏàÉ«Æ×ÖùÓë·½·¨¿ª·¢Ö¸ÄÏ
ÒѾÓÐ4È˻ظ´
2026ÉêÇ뿼ºË²©Ê¿×Ô¼ö-µ°°×ÖÊ×éѧ/AI/Ò©ÎïÉè¼Æ/AIDD/»¯Ñ§ÉúÎïѧ
ÒѾÓÐ1È˻ظ´
½ÓÊÜҩѧµ÷¼Á
ÒѾÓÐ11È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Çൺ¸ßУ2026ÕÐÉú˶ʿÑо¿Éú
+5/855
Õã½Å©ÁÖ´óѧÕÐÊÕµ÷¼Á
+1/81
Æ®ÔÚÃÀ¹ú£¬ÓеãÏë¼Ò
+1/65
ÉϺ£½»´ó»¯Ôº¹¦ÄÜ´ó·Ö×ÓÍŶÓÕÐ2026Äê˶ʿ¡¢ÁªÅà¡¢²©Ê¿ºó
+1/37
2026ÄêÖØÇ칤ÉÌ´óѧ¹ÜÀí¿ÆÑ§Ó빤³ÌרҵѧÊõ˶ʿÕÐÉúµ÷¼Á£¬·ç¾°×ÜÔÚÁø°µ»¨Ã÷´¦
+1/36
ÏæÌ¶´óѧ¡°¹ý³ÌÇ¿»¯ÓëÂÌÉ«»¯¹¤¡±´´ÐÂÍŶӲ¹ÕÐ2026ÄêÇïÈëѧ²©Ê¿Éú
+1/35
Ìì½ò¹¤Òµ´óѧº½¿Õº½Ì첩ʿÕÐÉú
+1/33
ÖпÆÔºÉú̬»·¾³Ñо¿ÖÐÐĹúÖØÊµÑéÊÒÕÐÆ¸¿Í×ùÑо¿Éú1-2Ãû
+1/31
ÉϺ£½»Í¨´óѧµç´ß»¯·½Ïò²©ºóÕÐÆ¸-ÓÐ﮵硢¸ß·Ö×Ó¡¢È¼ÁÏµç³Ø±³¾°ÕßÓÅÏÈ
+1/31
Call for paper: [Fermentation ¨C IF 3.3]
+2/30
º£ÄÏʦ·¶´óѧËïÔªÔªÀÏʦÕÐÉú²©Ê¿£¬Ãû¶î1~2¸ö£¬2026Äê9Ô·ÝÈëѧ£¨¹âµç/¹âÈÈ´ß»¯·½Ïò£©
+1/17
ҽѧ327·Öר˶µ÷¼Á
+1/16
¡¾Ô¤Ë¶¡¿¡¾Ô¤²©¡¿Çൺ´óѧÉúÎïÒ½Ò©´´ÐÂת»¯
+1/16
¡¾2026²©Ê¿ÕÐÉú/²©ºóÕÐÆ¸¡¿±±¾©º½¿Õº½Ìì´óѧÅ˱ë¿ÎÌâ×顪¡ªAIоƬÉè¼Æ·½Ïò
+1/11
¿ÎÌâ×éÕÐÊÕ»·¾³¼°Ïà¹Ø×¨Òµµ÷¼Á˶ʿÑо¿Éú£¨»¶ÓÓÅÐãѧÉú¼ÓÈ룩
+1/6
ÄÏÁÖ»¯¹¤ÔºÕÐÉêÇëÉóºËÖÆ²©Ê¿
+1/6
Çóµ÷¼Á£üÒ»Ö¾Ô¸¹ã¶«¹¤Òµ´óѧ¿ØÖƹ¤³Ì£ü×Ü·Ö355£ü±¾¿ÆµçÆø£üÓÐÏîÄ¿/¾ºÈü/ÂÛÎľÀú
+1/6
˫һÁ÷Ìì½ò¹¤Òµ´óѧµçÐÅѧԺÀîºèÇ¿½ÌÊÚÕÐÊÕ2026ÄêÉêÇëÉóºËÖÆ²©Ê¿3Ãû
+1/5
Öйú¿ÆÑ§Ôº¹ý³Ì¹¤³ÌÑо¿ËùÖúÀíÑо¿Ô±£¨Õýʽְ¹¤£©ºÍ²©Ê¿ºóÕÐÆ¸ÆôÊÂ
+1/5
º£ÄÏ´óѧÐìÔÂɽÀÏʦÕÐÉúµÚ¶þÅú²©Ê¿Ãû¶î2~3¸ö£¬2026Äê9Ô·ÝÈëѧ£¨¸ß¶ËÉ豸¿ª·¢·½Ïò£©
+1/2
yangjing561(½ð±Ò+4): 2011-01-14 16:07:03
|
Reference 1: Corbett, R.; Bordeau, K.J.; Helsley, G.C.; Szewczak, M.R.; Wilmot, C.A.; Chiang, Y.; Hartman, H.B.; Conway, P.G.; Glamkowski, E.J.; Strupczewski, J.T.; 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of iloperidone (HP 873). J Med Chem 1995, 38, 7, 1119-31. Reference 2: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J. (Aventis Pharmaceuticals, Inc.); N-(Aryloxyalkyl)heteroarylpiperidines and-heteroarylpiperazines, a process for their preparation and their use as medicaments. EP 0402644; JP 1991063263 . Reference 3: Strupczewski, J.T.; Helsley, G.C.; Chiang, Y.; Bordeau, K.J.; Glamkowski, E.J. (Aventis Pharmaceuticals, Inc.); Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics. EP 0542136; EP 0612318; EP 0730452; EP 0957102; EP 0959075; EP 0959076; EP 0963984; JP 1995501055; JP 1997511215; US 5364866; US 5776963; WO 9309102; WO 9511680 . Reference 4: Mucke, H.A.M.; Castaner, J.; Iloperidone. Drugs Fut 2000, 25, 1, 29. Reference 5: Strupczewski, J.T.; Allen, R.C.; Gardner, B.A. (Aventis Pharmaceuticals, Inc.); 3-(4-Piperidyl)-1,2-benzisoxazoles. US 4355037 . |
2Â¥2011-01-14 13:56:17
zsc
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- DRDEPI: 1
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 6652.4
- Ìû×Ó: 230
- ÔÚÏß: 278.2Сʱ
- ³æºÅ: 309535
yangjing561(½ð±Ò+4): 2011-01-14 16:07:11
|
http://www.accessdata.fda.gov/sc ... =Search.DrugDetails FDAÏà¹Ø×ÊÁÏ£¬ËµÃ÷Êé ÈýÏîÖØÒªÏà¹Ø×¨Àû£¬µÚÒ»ÏîרÀû£¬ÉêÇëºÅ£º90103721.4£¬ÉêÇëÈÕ£º1990.05.19 רÀûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN-(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,ËüÃǵÄÖÆ±¸·½·¨ÒÔ¼°ËüÃÇ×÷ΪҩÎïµÄÓ¦ÓᣵڶþÏîרÀû£¬ÉêÇëºÅ£º 00130979.X£¬ÉêÇëÈÕ£º1990.05.19 £¬×¨Àûµ½ÆÚʱ¼ä£º2010Äê05ÔÂ19ÈÕ£¬Ãû³Æ£ºN£(·¼Ñõ»ùÍé»ù)ÔÓ·¼»ùßÉ़°Ò»ÔÓ·¼»ùßÉàº,×÷ΪҩÎïµÄÓ¦ÓᣵÚÈýÏîרÀû£¬ÉêÇëºÅ£º94194302.X ÉêÇëÈÕ£º1994.10.27£¬×¨Àûµ½ÆÚʱ¼ä£º2014Äê10ÔÂ27ÈÕ£¬Ãû³Æ£º·¼ÔÓ»·»ùßßà¤Àà¡¢ßÁ¿©ÍéÀ༰ßßàºÀ༰Æä×÷Ϊ¿¹¾«Éñ²¡Ò©ºÍֹʹҩµÄÓÃ;¡£ http://www.drugfuture.com/fda/nda022192_001.html Õâ¸öÒ²¿ÉÒÔ |
3Â¥2011-01-14 14:07:11
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| Õâ¸öÒ©ÊDz»ÊÇÓÐÖйúµÄ¾§ÐÍרÀûºÍÓÃ;רÀû°¡£¿ |
4Â¥2011-05-11 17:03:04
¡ï
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
lk590(½ð±Ò+1): лл²ÎÓë 2011-09-13 12:44:36
|
ÓÃ;µÄרÀûºÜ¶à£¬»¹ÓÐһƪÊÇÌáµ½¾§Ð͵ÄרÀûwo 2004006886A2 |
5Â¥2011-05-12 10:31:02
6Â¥2011-09-13 10:00:56













»Ø¸´´ËÂ¥